UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 84

Sortiert nach

DNA repair inhibitors sensitize cells differently to high and low LET radiation

Scientific reports, 2021-12, Vol.11 (1), p.23257-23257, Article 23257

2021

Link zum Volltext

Verfügbarkeit prüfen

Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524

eLife, 2016-02, Vol.5

2016

Link zum Volltext

Verfügbarkeit prüfen

Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis

Molecular biology of the cell, 2007-10, Vol.18 (10), p.4024-4036

2007

Link zum Volltext

Verfügbarkeit prüfen

Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model

International journal of molecular sciences, 2021-05, Vol.22 (11), p.5570

2021

Link zum Volltext

Verfügbarkeit prüfen

Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models

Signal transduction and targeted therapy, 2018-04, Vol.3 (1), p.9-9, Article 9

2018

Link zum Volltext

Verfügbarkeit prüfen

Differential regulation of in vivo angiogenesis by angiotensin II receptors

The FASEB journal, 2003-11, Vol.17 (14), p.2061-2067

2003

Link zum Volltext

Verfügbarkeit prüfen

Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression

Oncogene, 1997-08, Vol.15 (6), p.669-676

1997

Link zum Volltext

Verfügbarkeit prüfen

Off-Target Decoding of a Multitarget Kinase Inhibitor by Chemical Proteomics

Chembiochem : a European journal of chemical biology, 2009-05, Vol.10 (7), p.1163-1174

2009

Link zum Volltext

Verfügbarkeit prüfen

Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction

Proceedings of the National Academy of Sciences - PNAS, 2019-02, Vol.116 (7), p.2551-2560

2019

Link zum Volltext

Verfügbarkeit prüfen

Anthranilic Acid Amides: A Novel Class of Antiangiogenic VEGF Receptor Kinase Inhibitors

Journal of medicinal chemistry, 2002-12, Vol.45 (26), p.5687-5693

2002

Link zum Volltext

Verfügbarkeit prüfen

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models

Molecular cancer therapeutics, 2020-01, Vol.19 (1), p.26-38

2020

Link zum Volltext

Verfügbarkeit prüfen

Mapping of the Sites for Ligand Binding and Receptor Dimerization at the Extracellular Domain of the Vascular Endothelial Growth Factor Receptor FLT-1

The Journal of biological chemistry, 1997-04, Vol.272 (16), p.10382-10388

1997

Link zum Volltext

Verfügbarkeit prüfen

Radiobiological effects of the alpha emitter Ra-223 on tumor cells

Scientific reports, 2019-12, Vol.9 (1), p.18489-11, Article 18489

2019

Link zum Volltext

Verfügbarkeit prüfen

Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation

Cancer research (Chicago, Ill.), 2019-11, Vol.79 (21), p.5640-5651

2019

Link zum Volltext

Verfügbarkeit prüfen

BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application

Molecular cancer therapeutics, 2012-10, Vol.11 (10), p.2265-2273

2012

Link zum Volltext

Verfügbarkeit prüfen

Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer

Journal of medicinal chemistry, 2021-08, Vol.64 (15), p.11651-11674

2021

Link zum Volltext

Verfügbarkeit prüfen

Alkoxyallene-based syntheses of preussin and its analogs and their cytotoxicity

Organic & biomolecular chemistry, 2019, Vol.17 (1), p.122-134

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 272: Synergistic activity of the ATR inhibitor BAY1895344 in combination with immune checkpoint inhibitors in preclinical tumor models

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.272-272

2019

Link zum Volltext

Verfügbarkeit prüfen

The Lab Oddity Prevails: Discovery of Pan-CDK Inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer

ChemMedChem, 2013-07, Vol.8 (7), p.1067-1085

2013

Link zum Volltext

Verfügbarkeit prüfen

SREBP-1 Mediates Activation of the Low Density Lipoprotein Receptor Promoter by Insulin and Insulin-like Growth Factor-I

The Journal of biological chemistry, 1996-03, Vol.271 (12), p.7128-7133

1996

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2077: Activity of DHODH inhibitor BAY2402234 in subcutaneous and intracranial models of SCLC

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.2077-2077

2021

Link zum Volltext

Verfügbarkeit prüfen

Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity

Molecular cancer therapeutics, 2016-04, Vol.15 (4), p.583-592

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3927: Radium-223 α-particle radiation: Characterization of the in vitro effects on cancer cells in monotherapy and in combination with DNA repair inhibitors

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3927-3927

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 84

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(80)

Publikationsform

Artikel
(83)
Buchkapitel
(1)

Sprache

Englisch
(84)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Science & Technology
(49)
Life Sciences & Biomedicine
(44)
Humans
(38)
Animals
(31)
Mice
(23)
Oncology
(18)
Cell Line, Tumor
(15)
Biochemistry & Molecular Biology
(14)
Chemistry, Medicinal
(13)
Pharmacology & Pharmacy
(13)
Biological And Medical Sciences
(12)
Female
(12)
Protein Kinase Inhibitors - Pharmacology
(11)
Protein Kinase Inhibitors - Chemistry
(10)
Vascular Endothelial Growth Factor A
(10)
Vascular Endothelial Growth Factors
(10)
Binding Sites
(9)
Cell Biology
(9)
Xenograft Model Antitumor Assays
(9)
Antineoplastic Agents - Chemistry
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

DNA repair inhibitors sensitize cells differently to high and low LET radiation

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer

Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524

Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis

Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model

Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models

Differential regulation of in vivo angiogenesis by angiotensin II receptors

Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression

Off-Target Decoding of a Multitarget Kinase Inhibitor by Chemical Proteomics

Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction

Anthranilic Acid Amides: A Novel Class of Antiangiogenic VEGF Receptor Kinase Inhibitors

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models

Mapping of the Sites for Ligand Binding and Receptor Dimerization at the Extracellular Domain of the Vascular Endothelial Growth Factor Receptor FLT-1

Radiobiological effects of the alpha emitter Ra-223 on tumor cells

Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation

BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application

Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer

Alkoxyallene-based syntheses of preussin and its analogs and their cytotoxicity

Abstract 272: Synergistic activity of the ATR inhibitor BAY1895344 in combination with immune checkpoint inhibitors in preclinical tumor models

The Lab Oddity Prevails: Discovery of Pan-CDK Inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer

SREBP-1 Mediates Activation of the Low Density Lipoprotein Receptor Promoter by Insulin and Insulin-like Growth Factor-I

Abstract 2077: Activity of DHODH inhibitor BAY2402234 in subcutaneous and intracranial models of SCLC

Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models

Abstract 3927: Radium-223 α-particle radiation: Characterization of the in vitro effects on cancer cells in monotherapy and in combination with DNA repair inhibitors

Suchergebnisse filtern